Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3431766 | 1.00 | SIGMAR1 (0.33) | SIGMAR1USP2MEN1KMT2AALDH1A1 | |
| SCHEMBL3429437 | 0.89 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL3428842 | 0.89 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL3428782 | 0.85 | SIGMAR1 (0.38) | SIGMAR1MEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL3429440 | 0.81 | MAPK1 (0.40) | SIGMAR1MEN1KMT2AALDH1A1GBA1 | |
| SCHEMBL14438561 | 0.81 | MAPK1 (0.40) | SIGMAR1MEN1KMT2AALDH1A1GBA1 | |
| SCHEMBL3428847 | 0.81 | MAPK1 (0.40) | SIGMAR1MEN1KMT2AALDH1A1GBA1 | |
| SCHEMBL3427122 | 0.78 | GRIN2D (0.31) | — | |
| SCHEMBL24802087 | 0.77 | SIGMAR1 (0.35) | SIGMAR1MEN1KMT2AGBA1SMN1; SMN2 | |
| SCHEMBL25873415 | 0.77 | SIGMAR1 (0.35) | SIGMAR1MEN1KMT2AGBA1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691867-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| EP-1613619-B1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| US-20060270692-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270692-A1 | Chemical compounds | CCNI, MKI67, TP53 | SIGMAR1 3443/4885USP2 4228/4885MEN1 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.